GHK-Cu

GHK-Cu is the compound that most honestly fits the phrase 'restoring what the body already had.' The plasma decline from 200 to 80 ng/mL between ages 20 and 60 is documented, reproducible, and correlated with declining tissue repair capacity. The TGF-beta collagen synthesis mechanism is replicated across multiple labs. The gene expression breadth is confirmed by independent researchers using the Broad Institute's own public database. The topical human evidence is real — genuine RCTs with biopsy-confirmed or imaging-confirmed outcomes, outperforming tretinoin in the one head-to-head comparison that exists. None of this is marketing.

The central tension is also real. The community has collectively decided to extrapolate from the topical evidence base to a systemic injectable use case that the published literature does not directly speak to. That extrapolation is not irrational: an endogenous plasma signal whose decline tracks with the deterioration of the functions it regulates has a coherent restoration argument. But the restoration logic is not clinical evidence for the injectable route. Readers who want to act within the evidence can do so confidently with topical protocols. Readers who choose injectable protocols are making an informed extrapolation — not a validated clinical decision.

What gives GHK-Cu stronger standing than most research peptides is the quality of its independent corroboration. Campbell's COPD reversal, Hong's colorectal cancer CMap finding, Bossak-Ahmad's copper chemistry, Abdulghani's head-to-head comparison, the 2023 split-face RCT — these are not Pickart's work. They are independent researchers arriving at consistent findings about the same compound. That distributed corroboration is rare in this space.